Results 121 to 130 of about 4,593,278 (410)
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study [PDF]
Background Eribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy. Methods Patients with primary triple
Apolone G.+18 more
core +2 more sources
Alpha‐fetoprotein‐producing gastric cancer (AFPGC), a rare and aggressive subtype of gastric cancer, presents a high risk of liver metastasis. This study introduces the ANLiM score, a blood biomarker‐based predictive indicator for assessing liver metastasis and immunotherapy response.
Yongfeng Ding+26 more
wiley +1 more source
NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
More than 70 % of patients with breast cancer have estrogen-receptor-positive tumors (ER+) and are considered hormone- sensitive. That is why a vast majority of patients with early operable tumors receive adjuvant endocrine therapy.
V. F. Semiglazov+13 more
doaj +1 more source
Diffusion Tensor Imaging for Assessment of Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. [PDF]
In this study, the prognostic significance of tumor metrics derived from diffusion tensor imaging (DTI) was evaluated in patients with locally advanced breast cancer undergoing neoadjuvant therapy.
Harnish, Roy+6 more
core +1 more source
Adjuvant completion with early initiation may contribute to the improved survival of patients with pancreatic ductal adenocarcinoma. Abstract Aim To evaluate the prognostic effect of initiation timing and completion of adjuvant therapy in patients with pancreatic ductal adenocarcinoma.
Kenjiro Okada+9 more
wiley +1 more source
Surgical resection remains a mainstay in the treatment of malignant solid tumors. However, the use of neoadjuvant treatments, including chemotherapy, radiotherapy, phototherapy, and immunotherapy, either alone or in combination, as a preoperative ...
Xiaogang Qu+5 more
doaj
Prolonged administration of antimicrobial prophylaxis might not be effective to prevent surgical site infections after distal pancreatectomy compared to intraoperative or up to 24‐h administration. Abstract Background Antimicrobial prophylaxis is routinely administered in patients undergoing distal pancreatectomy, with cephalosporins being the most ...
Kenjiro Okada+8 more
wiley +1 more source
Neoadjuvant therapy for esophageal cancer
Esophageal cancer is increasing in incidence more than any other visceral malignancy in North America. Adenocarcinoma has become the most common cell type. Surgery remains the primary treatment modality for locoregional disease. Overall survival with surgery alone has been dismal, with metastatic disease the primary mode of treatment failure after an ...
James P. Neifeld+2 more
openaire +3 more sources
Background Although neoadjuvant therapy followed by esophagectomy is well-established as being superior to upfront esophagectomy when locoregional lymph node (LN) metastasis is present in esophageal cancer, upfront esophagectomy without neoadjuvant ...
Jae Kil Park+3 more
doaj +1 more source
Importance Patients with locally advanced pancreatic cancer have historically poor outcomes. Evaluation of a total neoadjuvant approach is warranted. Objective To evaluate the margin-negative (R0) resection rate of neoadjuvant FOLFIRINOX (fluorouracil,
Janet E. Murphy+30 more
semanticscholar +1 more source